As IRAK inhibitor therapy was shown to induce BCL-2 expression, suggesting a potential resistance mechanism, Rhyasen and colleagues provide initial evidence to support combination therapy of an IRAK inhibitor with a BCL-2 antagonist in both in vitro and in vivo models of MDS. This evidence concerns the gene BCL2 and myelodysplastic syndrome.